Europe In-Vitro Diagnostics Market Size (2024 - 2029)

The European in-vitro diagnostics market is anticipated to experience growth driven by the increasing prevalence of chronic and infectious diseases, which boosts the demand for early and precise diagnostic techniques. The market's expansion is further supported by the introduction of advanced point-of-care testing kits and heightened awareness initiatives for chronic diseases, encouraging the adoption of in-vitro diagnostics products. Despite these growth drivers, the market faces challenges due to stringent regulations and complex reimbursement processes, which may hinder its overall expansion.

Market Size of Europe In-Vitro Diagnostics Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Europe In-Vitro Diagnostics Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 5.50 %
Market Concentration Medium

Major Players

Europe In-Vitro Diagnostics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Europe In Vitro Diagnostics (IVD) Market Analysis

The European in-vitro diagnostics market is expected to register a CAGR of 5.5% over the forecast period.

COVID-19 has significantly impacted supply-demand in the in-vitro diagnostics market in Europe as it was one of the severely affected regions. Increased number of in-vitro diagnostics testing for the diagnosis of COVID-19 symptoms augmented the adoption rate of these instruments. For instance, according to a report by the Gov.UK, almost 7.6 million lateral flow device tests were performed between 8 April and 21 April 2021 in England. This high volume of in-vitro diagnostic (IVD) tests in Europe for the precise diagnostics of COVID symptoms augmented the market's growth during the pandemic. However, the market growth remained stable during the post-pandemic period in Europe due to the reduced demand for COVID-19 in-vitro diagnostic testing and decreased confirmed cases in the region.

One of the major factors fueling market growth is the rising prevalence of chronic diseases throughout Europe. An increasing number of patients suffering from chronic diseases, including cancer, cardiovascular diseases, diabetes, and others, is augmenting the demand for early diagnosis. Further, the rising prevalence of several infectious diseases, such as influenza, tuberculosis, hepatitis, and others, is also fueling the demand for in-vitro diagnostics tests. For instance, according to European Centre for Disease Prevention and Control (ECDC), the number of reported influenza cases in Europe was 4,690 in the 2021-2022 season, significantly higher than the previous year. Also, according to data from International Diabetes Federation in 2021, the prevalence of diabetes among adults in Europe in 2021 was 9.2%, which was anticipated to increase to 9.8% by 2030. This increasing patient pool is growing the demand for precise diagnostics techniques, including molecular diagnostics, immunodiagnostics, and others, for specific outcomes, early detection, and reducing the rate of false positives during diagnostic procedures, which drive the demand for advanced in-vitro diagnostics products in Europe.

Further, the launch of advanced point-of-care testing kits for different indications, which are simple to use and highly efficient, is expected to boost the adoption of in-vitro diagnostics products in the region, thereby fuelling growth in the market. For instance, in July 2021, QuantuMDx Group Ltd. launched Q-POC in Europe to offer precise and rapid results for SARS-COV-2 within 30 minutes.

The increasing number of initiatives for the awareness of chronic diseases also increases the demand and adoption rate of in-vitro diagnostics tests for early detection. For instance, in August 2022, NHS organized a lung cancer awareness campaign to increase disease awareness and the importance of early detection through the available diagnostic procedures.

Therefore, owing to the high burden of chronic and infectious diseases, the launch of advanced products, and growing awareness, the demand for in-vitro diagnostics (IVD) products is expected to increase in Europe over the forecast period. However, stringent regulations and cumbersome reimbursement procedures will restrain the market's growth.

Europe In Vitro Diagnostics (IVD) Industry Segmentation

As per the scope of this report, in-vitro diagnostics are the tests performed in laboratories or by consumers at home to diagnose, monitor, screen, and assess various diseases, conditions, or infections. IVD products are reagents, instruments, and systems intended for use in diagnosing diseases or other conditions. IVDs form an essential part of the current healthcare system. They reduce hospital stays and the need to recuperate. The Europe In-Vitro Diagnostics Market is Segmented by Test Type (Clinical Chemistry, Molecular Diagnostics, Immuno Diagnostics, Hematology, and Other Test Types), Product (Instruments, Reagents, and Other Products), Usability (Disposable IVD Devices and Reusable IVD Devices), Application (Infectious Disease, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, Nephrology, and Other Applications), End User (Diagnostic Laboratories, Hospitals and Clinics, and Other End Users) and Geography (Germany, United Kingdom, France, Italy, Spain, and the Rest of Europe). The report offers the value (in USD million) for the above segments.

By Test Type
Clinical Chemistry
Molecular Diagnostics
Hematology
Immuno Diagnostics
Other Test Types
By Product
Instrument
Reagents
Other Products
By Usability
Disposable IVD Devices
Reusable IVD Devices
By Application
Infectious Disease
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Disease
Nephrology
Other Applications
By End User
Diagnostic Laboratories
Hospitals and Clinics
Other End Users
Geography
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region Or Segment?
Customize Now

Europe In-Vitro Diagnostics Market Size Summary

The European in-vitro diagnostics (IVD) market is poised for steady growth, driven by the increasing prevalence of chronic and infectious diseases, alongside advancements in diagnostic technologies. The market experienced a surge during the COVID-19 pandemic due to heightened testing demands, which has since stabilized post-pandemic. The rising incidence of conditions such as cancer, cardiovascular diseases, and diabetes is propelling the demand for early and precise diagnostic solutions. Additionally, the introduction of advanced point-of-care testing kits and initiatives to raise awareness about chronic diseases are further boosting market expansion. Despite these positive trends, the market faces challenges from stringent regulations and complex reimbursement processes.

In the United Kingdom, the IVD market is expected to grow significantly, supported by the increasing adoption of point-of-care diagnostics and the development of healthcare infrastructure. The rising prevalence of chronic diseases and the expanding geriatric population are key factors driving demand for IVD devices. The establishment of new diagnostic centers and the introduction of advanced diagnostic instruments are also contributing to market growth. The competitive landscape in Europe is characterized by the presence of major players like Roche Diagnostics and Abbott Laboratories, who are focusing on strategic partnerships and product innovations to strengthen their market position.

Explore More

Europe In-Vitro Diagnostics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 High Prevalence of Chronic Diseases

      2. 1.2.2 Increasing Demand for Point-of-care Diagnostics

      3. 1.2.3 Technological Advancements in In-Vitro Diagnostics Devices

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulations

      2. 1.3.2 Cumbersome Reimbursement Procedures

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Test Type

      1. 2.1.1 Clinical Chemistry

      2. 2.1.2 Molecular Diagnostics

      3. 2.1.3 Hematology

      4. 2.1.4 Immuno Diagnostics

      5. 2.1.5 Other Test Types

    2. 2.2 By Product

      1. 2.2.1 Instrument

      2. 2.2.2 Reagents

      3. 2.2.3 Other Products

    3. 2.3 By Usability

      1. 2.3.1 Disposable IVD Devices

      2. 2.3.2 Reusable IVD Devices

    4. 2.4 By Application

      1. 2.4.1 Infectious Disease

      2. 2.4.2 Diabetes

      3. 2.4.3 Cancer/Oncology

      4. 2.4.4 Cardiology

      5. 2.4.5 Autoimmune Disease

      6. 2.4.6 Nephrology

      7. 2.4.7 Other Applications

    5. 2.5 By End User

      1. 2.5.1 Diagnostic Laboratories

      2. 2.5.2 Hospitals and Clinics

      3. 2.5.3 Other End Users

    6. 2.6 Geography

      1. 2.6.1 Germany

      2. 2.6.2 United Kingdom

      3. 2.6.3 France

      4. 2.6.4 Italy

      5. 2.6.5 Spain

      6. 2.6.6 Rest of Europe

Europe In-Vitro Diagnostics Market Size FAQs

The Europe In-Vitro Diagnostics Market is projected to register a CAGR of 5.5% during the forecast period (2024-2029)

Sysmex Corporation, QIAGEN, BioMérieux SA, F. Hoffmann-La Roche Ltd and Illumina, Inc. are the major companies operating in the Europe In-Vitro Diagnostics Market.

Europe IVD Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)